Drug Profile
Research programme: gene therapeutics - Kadmon Gene Therapy Holdings
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Kadmon Corporation
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Blindness
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Blindness in USA
- 01 May 2015 Preclinical trials in Blindness in USA (unspecified route) prior to May 2015